VERA THERAPEUTICS INC
NASDAQ: VERA (Vera Therapeutics, Inc.)
Last update: 1 hour ago25.94
-2.52 (-8.85%)
| Previous Close | 28.46 |
| Open | 28.09 |
| Volume | 2,121,733 |
| Avg. Volume (3M) | 1,548,256 |
| Market Cap | 1,655,585,920 |
| Price / Book | 3.98 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -3.00 |
| Total Debt/Equity (MRQ) | 10.18% |
| Current Ratio (MRQ) | 27.68 |
| Operating Cash Flow (TTM) | -155.26 M |
| Levered Free Cash Flow (TTM) | -97.14 M |
| Return on Assets (TTM) | -23.46% |
| Return on Equity (TTM) | -39.49% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vera Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -1.5 |
| Average | 0.88 |
|
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 3.97% |
| % Held by Institutions | 112.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Avoro Capital Advisors Llc | 30 Jun 2025 | 6,300,000 |
| Price T Rowe Associates Inc /Md/ | 30 Jun 2025 | 4,479,717 |
| Kynam Capital Management, Lp | 30 Jun 2025 | 3,426,887 |
| Deerfield Management Company, L.P. | 30 Jun 2025 | 3,348,117 |
| Vestal Point Capital, Lp | 30 Jun 2025 | 3,100,000 |
| Sofinnova Investments, Inc. | 30 Jun 2025 | 2,793,987 |
| Woodline Partners Lp | 30 Jun 2025 | 2,608,372 |
| Eversept Partners, Lp | 30 Jun 2025 | 2,383,055 |
| Tang Capital Management Llc | 30 Jun 2025 | 1,350,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 53.00 (JP Morgan, 104.32%) | Buy |
| Median | 50.50 (94.68%) | |
| Low | 48.00 (B of A Securities, 85.04%) | Buy |
| Average | 50.50 (94.68%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 25.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 16 Oct 2025 | 48.00 (85.04%) | Buy | 30.51 |
| JP Morgan | 07 Aug 2025 | 53.00 (104.32%) | Buy | 19.72 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 22 Oct 2025 | Announcement | Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET |
| 17 Oct 2025 | Announcement | Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025 |
| 10 Oct 2025 | Announcement | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 05 Sep 2025 | Announcement | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 26 Aug 2025 | Announcement | Vera Therapeutics to Participate at Upcoming Investor Conferences |
| 08 Aug 2025 | Announcement | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |